Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Leukemia, B-Cell × ibrutinib × Clear all

Phase

Phase 2 3 Phase 1 3 Phase 3 2 Phase 4 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell 1 Leukemia, B-Cell 1 Graft vs Host Disease 1

Interventions

ofatumumab 1 obinutuzumab 1 ibrutinib 1 acalabrutinib 1 Rituximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03229200 2025-10-30

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Pharmacyclics Switzerland GmbH

Phase 4 Active not recruiting

LymphoidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡